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tions based on a single treatment feature such as cost, or select
the current-treatment alternative in all questions. We used probit
models to identify the chracteristics of subjects who are more
likely to reject scenarios and controlled for scenario rejection in
estimating preference models. RESULTS: 463 respondents com-
pleted the survey. 12.4% of respondents did not answer the
trade-off questions, 40.6% dominated on price, and 51.3%
chose their current treatment in all trade-off questions. Respon-
dents were less likely to reject scenarios if they had higher
incomes (p < 0.000), more education (p < 0.000), were recently
diagnosed with RA (p = 0.006), and if the cost of their current
treatment was high (p < 0.000). Respondents who currently use
an oral medication are less likely and respondents who currently
use an injected or infused treatment are more likely to always
pick current treatment. Controlling for price-dominant subjects
increases willingness to pay for the “chance that the medicine
works well 100% of the time” from $217 ($166–$268) to $471
($396–$545) per month. CONCLUSION: Scenario rejection is
a form of selection bias. Rejectors provide no trade-off infor-
mation for estimating treatment preferences. Rejection is corre-
lated with several observable variables, which makes it possible
to control for potential bias in preference estimation. Control-
ling for price-dominant subjects can have a large impact on WTP
estimates.
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OBJECTIVES: To identify the most reliable approach for 
measuring dose escalation by comparing results from different
methods that may affect clinical and drug utilization decisions.
METHODS: Five methods of quantifying dose escalation were
explored which compared: 1) weekly dose of last to ﬁrst pre-
scription; 2) average weekly dose of all prescriptions to standard
dose; 3) weekly dose of subsequent prescriptions to ﬁrst pre-
scription and 3a) deﬁning dose escalation as °Y´2 instances of
dose increase; 3b) deﬁning dose escalation by proportional dose
increase (15%, 30%, or 50%); and 3c) calculating dose escala-
tion as percent of patient-weeks. The example is based on claims
data from 2002 to 2004, using RA patients newly initiated anti-
TNFα (Enbrel or Humira) treatment with one year follow-up.
Separate analyses were conducted for patients started on stan-
dard and high doses. RESULTS: For those who started on stan-
dard dose, dose escalation by method 1 and 2 was 6.2% and
8.4% for Enbrel patients (n = 1339) and, 13.7% and 26.6% for
Humira patients (n = 417). Dose escalation by method 3a was
8.1% for Enbrel and 18.9% for Humira. Dose escalation by
method 3b (with threshold of 15%, 30%, and 50%) ranged from
5.6% to 7.7% for Enbrel and 16.1% to 18.5% for Humira,
respectively. Percent patient-time approach of 3c provides weekly
incidences of dose escalation and exhibits a divergent pattern of
dose escalation between the treatment groups over time, which
diverges at about the 12th week of treatment. Dose escalation
was uncommon in patients started with high dose. CONCLU-
SION: Estimate of dose escalation is method dependent. Simple
approaches such as comparing last and ﬁrst prescription were
unable to capture the full extent of dose escalation. Use of mul-
tiple methods, such as method 3 and method 2 are recommended
as the latter will also address dosing for patients initiated with
high doses.
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OBJECTIVES: Evaluate a patient Formulary Notiﬁcation
Program (FNP) designed to encourage use of lower cost, clini-
cally equivalent generic alternatives among non-formulary 
atorvastatin users. METHODS: This was a cross-sectional, case-
control study conducted in a commercially insured population,
targeting current atorvastatin users (date of last ﬁll + days supply
within 30 days of targeting). The case group received one of two
letter-based Patient Communications (PCs) depending on
channel of most current prescription ﬁll (target prescription).
The PCs informed patients of lower cost, clinically equivalent
generic alternatives. Patients in retail pharmacies (n = 27,449)
received information on copayment savings from generic use in
retail. Patients in Home Delivery (HD) (n = 25,274) received
information on savings from ﬁlling generic alternatives in HD.
The PCs were mailed in July 2006 soon after availability of
generic simvastatin. The control group consisted of current ator-
vastatin users (at time of case group targeting) who were not
enrolled in a client that implemented the FNP. Control group
members were matched to case group based on distribution
channel [retail (n = 3186)/HD (n = 1012)] of target prescription.
Prescription claims were examined through October 2006 for the
outcome of switching to generic statin. Bivariate and logistic
regression analyses were used to assess research objective.
RESULTS: In retail, 11.9% of cases switched to generic statin
compared to 4.8% in control group (p < 0.001). In HD, 20.6%
of cases switched to generic statin compared to 8.1% in control
group (p < 0.001). Controlling for demographic and plan design,
patients who received PCs in retail had 64% greater odds
(95%CI: 1.48–1.81) of ﬁlling generics relative to controls.
Patients receiving PCs in HD had 81% greater odds (95%CI:
1.60–2.05) of ﬁlling generics in HD compared to respective con-
trols. CONCLUSION: Informing patients of copayment savings
from generic alternatives soon after patent expiration of a
popular branded statin, is an effective strategy to encourage
greater generic statin use.
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OBJECTIVES: To investigate and to quantify the inﬂuence 
prescription cost-sharing has on medication reﬁll persistence 
by using two antihypertensive therapeutic classes: ACEs
(angiotensin converting enzyme inhibitors) and ARBs
(angiotensin II receptor blockers). METHODS: This is an obser-
vational cohort study utilizing a commercial insurer’s integrated
medical and pharmacy claims database supplemented with
public ﬁles. Members were new users of ACE and ARB single
agents between January 1 and June 30, 2004. Medication reﬁll
persistence was measured three ways: total number of days
without medication; proportion of days covered (PDC) with a
cutoff point of 80%; and number of days to the ﬁrst gap of more
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than 15 days in medication coverage. Three statistical models
corresponding to the three measures of medication reﬁll persis-
tence were performed: Tobit model, logistic regression, and 
survival analysis. Control variables included demographic and
social economic information, health status, medication condi-
tions, health service utilization, and drug beneﬁt characteristics.
RESULTS: The study included 1549 members, 42.0% female,
mean age 55.7 years, with member cost-sharing of about $12
per 30 days supply. For every $1 increase in 30 day average cost-
sharing, total gap increased by 2.7% (transferred Tobit coefﬁ-
cient = 0.027, 95% CI = [0.011, 0.043], p = 0.001); the odds of
non-persistence (PDC < 80%) increased by 2.5% (OR = 1.025,
95% CI = [1.007, 1.042], p = 0.005); and the risk to have a gap
of more than 15 days increased by 1.7% (HR = 1.017, 95% CI
= [1.007, 1.027], p = 0.001). CONCLUSION: Prescription cost-
sharing was associated with a signiﬁcant and negative impact 
on medication reﬁll persistence after controlling for other con-
founders. It is important for health plans and self insured
employers to consider the implications of member contribution
on medication reﬁll persistence when making pharmacy beneﬁt
design decisions.
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OBJECTIVES: To evaluate the long-term health outcomes of
ACS patients taking clopidogrel and aspirin, either alone or 
in combination, within the California Medicaid population.
METHODS: A retrospective claims study was conducted for the
10-year period from 1995–2004. Patients were ≥19 years of age,
with ≥6 months of continuous eligibility prior to index date, and
≥1 month of continuous eligibility after index date. Patients hos-
pitalized with UA or NSTEMI were identiﬁed using ICD-9 codes
and divided into 3 subgroups: clopidogrel-only (CO), aspirin-
only (AO), and clopidogrel/aspirin (CA). Cox proportional-
hazard models were used to estimate hazard ratios (HR) for 
time to death, major bleeding events (MBE; ICD-9 codes
531.x1–535.x1), re-hospitalization, and revascularization with
covariate adjustment. The unadjusted time-to-event curves were
estimated using Kaplan-Meier (KM) techniques. RESULTS: The
UA/NSTEMI study population included 6448 patients. KM
curves showed no difference in time to MBE among the 3 groups.
With AO (n = 3738) serving as the baseline, HR for CA (n =
2071) was 1.05 (P = 0.65); HR for CO (n = 639) was 0.985 (P
= 0.93). The KM curves for CO and AO showed no difference
in time to death. However, HR for CA was 0.706 (P = 0.0030),
indicating that patients taking both drugs had a roughly 30%
lower risk of death compared with patients taking AO. In con-
trast, CA had a 50% higher risk of re-hospitalization (HR =
1.50, P < 0.0001) and revascularization (HR = 1.51, P < 0.0001)
than AO. No statistically signiﬁcant differences in risk were
found between CO and AO for re-hospitalization (HR = 0.80, P
= 0.18) or revascularization (HR = 1.18, P = 0.18). CONCLU-
SION: The results suggest patients taking clopidogrel or aspirin,
either alone or in combination, have similar long-term bleeding
risk. The combination of clopidogrel and aspirin may reduce the
risk of death compared with either drug alone. However, com-
bination therapy did not lead to a decrease in re-hospitalization
or revascularization compared with either drug alone.
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OBJECTIVES: On July 12, 2005 the Arkansas Medicaid
program implemented a prior approval policy for calcium
channel blockers (CCBs) in which Diltiazem ER, Dynacirc CR,
Nifedipine ER, XL, CC, CR, Norvasc, and Verapamil SR, SA,
were the preferred drugs. The objective of this study was to 
estimate the impact of this policy on CCB expenditures.
METHODS: This study utilized a time series panel design to
evaluate the impact of the policy using Arkansas Medicaid
administrative claims data obtained from January 2003 through
May 2006. Auto-Regressive Integrated Moving Average
(ARIMA) time series models were speciﬁed using monthly pre-
scription expenditures and utilization in the pre-policy period
(January 2003–June 2005) to forecast expenditures and utiliza-
tion in the post-policy period. The Medicaid payer perspective
was used and all prescription costs were calculated based on the
amount paid for each claim adjusted for product speciﬁc CMS
rebates. RESULTS: The average forecast expenditures for 
CCBs for August 2005–May 2006 was $426,706 (95%CI:
410,356–443,055) per month and observed expenditures were
$331,547 indicating that the policy change was associated with
a 22% reduction in CCB expenditures or $95,159 (95%CI:
78,809–111,508) per month. The average monthly savings were
$114,521 prior to January 2006 and were $75,796 after
Medicare dual eligibles began receiving Part-D beneﬁts. Non-sig-
niﬁcant reductions in CCB utilization were observed in the initial
4 months following the policy, however by May 2006, 4065
(95%CI: 3811–4319) recipients were expected to be taking
CCBs but only 3046 actually had a CCB prescription ﬁlled.
CONCLUSION: This CCB preferred drug list resulted in sub-
stantial savings of approximately $100,000 per month. Some of
the savings appear to be a result of reduced utilization of CCBs
which may indicate that other cardiovascular drugs may have
been used in place of CCBs or CCB discontinuation.
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OBJECTIVES: The Medicare Modernization Act explicitly ruled
out the possibility that the federal government could directly
negotiate drug prices as an effective way to contain costs for Part
D. Recent changes in the leadership of congress have led to a
reemergence of debate on this issue. Taking a societal perspec-
tive, we sought to quantify how much money for prescription
drugs could be saved among the elderly if prices nationwide were
equivalent to 2006 Federal Supply Schedule (FSS) prices for
several of the top selling prescription drug classes. METHODS:
Cross-sectional analysis of the nationally representative Medical
Expenditure Panel Survey, 2004. Adults > 64 years who ﬁlled a
prescription for any drug within the following classes were
included: Angiotensin Receptor Blockers, ACE inhibitors, HMG-
CoA Reductase Inhibitors (Statins), Proton Pump Inhibitors,
Non-Steroidal Anti-inﬂammatory, Histamine-2 Receptor Antag-
onists, Dihydropyridine Calcium Channel Blockers, and Steroid
Inhalers (n = 2198 individuals). The average price/pill for each
